Last reviewed · How we verify
single dose of UC-MSCs
LiveKidney.Bio's single dose of UC-MSCs is a promising cell therapy with multiple ongoing clinical trials across various indications, including COVID-19 ARDS, ALS, and diabetic nephropathy. The therapy has shown potential in Phase 1 and Phase 2 studies, with a focus on safety and efficacy. No FDA approval yet, but strong pipeline and potential for significant market impact.
At a glance
| Generic name | single dose of UC-MSCs |
|---|---|
| Sponsor | LiveKidney.Bio |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- single dose of UC-MSCs CI brief — competitive landscape report
- single dose of UC-MSCs updates RSS · CI watch RSS
- LiveKidney.Bio portfolio CI